Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Supportive Care

Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT

Bone Marrow Transplantation volume 49, pages 950–954 (2014)Cite this article

Subjects

Abstract

Application of G-CSF in AML is controversial as leukemic blasts may express receptors interacting with the cytokine, which may stimulate leukemia growth. We retrospectively analyzed the impact of G-CSF use to accelerate neutrophil recovery after auto-SCT on outcome. Adults with AML in first CR autografted between 1994 and 2010 were included. Nine hundred and seventy two patients were treated with G-CSF after auto-SCT whereas 1121 were not. BM and PB were used as a source of stem cells in 454 (22%) and 1639 (78%) cases, respectively. The incidence of relapse at 5 years in the BM-auto-SCT group was 38% for patients receiving post-transplant G-CSF and 43% for those not treated with G-CSF, P=0.46. In the PB-auto-SCT cohort, respective probabilities were 48% and 49%, P=0.49. No impact of the use of G-CSF could be demonstrated with respect to the probability of leukemia-free survival: in the BM-auto-SCT group, 51% for G-CSF(+) and 48% for G-CSF(−), P=0.73; in PB-auto-SCT group, 42% for G-CSF(+) and 43% for G-CSF(−), P=0.83. Although G-CSF administration significantly shortened the neutropenic phase, no beneficial effect was observed with regard to non-relapse mortality. In patients with AML, the use of G-CSF after auto-SCT is not associated with increased risk of relapse irrespective of the source of stem cells used.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187–3205.

    Article  CAS  Google Scholar 

  2. Breems DA, Löwenberg B . Acute myeloid leukemia and the position of autologous stem cell transplantation. Semin Hematol 2007; 44: 259–266.

    Article  Google Scholar 

  3. Seshadri T, Keating A . Is there a role for autotransplants in AML in first remission? Biol Blood Marrow Transplant 2009; 15: 17–20.

    Article  Google Scholar 

  4. Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012; 47: 906–923.

    Article  CAS  Google Scholar 

  5. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85–86.

    Article  CAS  Google Scholar 

  6. Feller N, Schuurhuis GJ, van der Pol MA, Westra G, Weijers GW, van Stijn A et al. High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome. Leukemia 2003; 17: 68–75.

    Article  CAS  Google Scholar 

  7. Vellenga E, Young DC, Wagner K, Wiper D, Ostapovicz D, Griffin JD . The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood 1987; 69: 1771–1776.

    CAS  PubMed  Google Scholar 

  8. Löwenberg B, Touw IP . Hematopoietic growth factors and their receptors in acute leukemia. Blood 1993; 81: 281–292.

    PubMed  Google Scholar 

  9. Gooley TA, Leisenring W, Crowley JA, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 665–706.

    Article  Google Scholar 

  10. Fine JP, Gray RJ . A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.

    Article  Google Scholar 

  11. Gorin NC, Labopin M, Blaise D, Reiffers J, Meloni G, Michallet M et al. Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. J Clin Oncol 2009; 27: 3987–3993.

    Article  Google Scholar 

  12. Graf M, Hecht K, Reif S, Pelka-Fleischer R, Pfister K, Schmetzer H . Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. Eur J Haematol 2004; 72: 89–106.

    Article  CAS  Google Scholar 

  13. Majhail NS, Bajorunaite R, Lazarus HM, Wang Z, Klein JP, Zhang MJ et al. High probability of long-term survival in 2-year survivors of autologous hematopoietic cell transplantation for AML in first or second CR. Bone Marrow Transplant 2011; 46: 385–392.

    Article  CAS  Google Scholar 

  14. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997; 90: 4710–4718.

    CAS  PubMed  Google Scholar 

  15. Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 1998; 91: 3607–3615.

    CAS  PubMed  Google Scholar 

  16. Usuki K, Urabe A, Masaoka T, Ohno R, Mizoguchi H, Hamajima N et al. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. Br J Haematol 2002; 116: 103–112.

    Article  CAS  Google Scholar 

  17. Alonzo TA, Kobrinsky NL, Aledo A, Lange BJ, Buxton AB, Woods WG . Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children’s Cancer Group. J Pediatr Hematol Oncol 2002; 24: 627–635.

    Article  Google Scholar 

  18. Kutlay S, Beksac M, Dalva K, Ilhan O, Koc H, Akan H et al. The detection of flow cytometric G-CSF receptor expression and it’s effect on therapy in acute myeloid leukemia. Leuk Lymphoma 2003; 44: 791–795.

    Article  CAS  Google Scholar 

  19. Wheatley K, Goldstone AH, Littlewood T, Hunter A, Burnett AK . Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. Br J Haematol 2009; 146: 54–63.

    Article  CAS  Google Scholar 

  20. Beksac M, Ali R, Ozcelik T, Ozcan M, Ozcebe O, Bayik M et al. Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trial. Leuk Res 2011; 35: 340–345.

    Article  CAS  Google Scholar 

  21. Gurion R, Belnik-Plitman Y, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I et al. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev 2011; 7: CD008238.

    Google Scholar 

  22. Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006; 24: 4499–4506.

    Article  CAS  Google Scholar 

  23. Ehlers S, Herbst C, Zimmermann M, Scharn N, Germeshausen M, von Neuhoff N et al. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol 2010; 28: 2591–2597.

    Article  CAS  Google Scholar 

  24. White SM, Ball ED, Ehmann WC, Rao AS, Tweardy DJ . Increased expression of the differentiation-defective granulocyte colony-stimulating factor receptor mRNA isoform in acute myelogenous leukemia. Leukemia 1998; 12: 899–906.

    Article  CAS  Google Scholar 

  25. Beekman R, Touw IP . G-CSF and its receptor in myeloid malignancy. Blood 2010; 115: 5131–5136.

    Article  CAS  Google Scholar 

  26. Stahel RA, Jost LM, Cerny T, Pichert G, Honegger H, Tobler A et al. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 1994; 12: 1931–1938.

    Article  CAS  Google Scholar 

  27. Linch DC, Milligan DW, Winfield DA, Kelsey SM, Johnson SA, Littlewood TJ et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol 1997; 99: 933–938.

    Article  CAS  Google Scholar 

  28. Schmitz N, Ljungman P, Cordonnier C, Kempf C, Linkesch W, Alegre A et al. Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial. Bone Marrow Transplant 2004; 34: 955–962.

    Article  CAS  Google Scholar 

  29. Dekker A, Bulley S, Beyene J, Dupuis LL, Doyle JJ, Sung L . Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006; 24: 5207–5215.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice, Poland

    T Czerw & S Giebel

  2. Clinical Hematology and Cellular Therapy Department, Hopital Saint-Antoine APHP, Paris, France

    M Labopin, N-C Gorin & M Mohty

  3. INSERM UMRs 938, Paris, France

    M Labopin, N-C Gorin & M Mohty

  4. Université Pierre et Marie Curie (UPMC, Paris VI), Paris, France

    M Labopin, N-C Gorin & M Mohty

  5. Unité de transplantation et de thérapie cellulaire, Institut Paoli-Calmettes, Marseille, France

    D Blaise

  6. Hématologie clinique et Thérapie celllulaire, Hôpital Haut-Lévêque, Pessac, France

    P-Y Dumas

  7. Dipartimento Biotecnologie Cellulari ed Ematologia, Università ‘LaSapienza’, Rome, Italy

    R Foa

  8. CHU Department Hematologie, Hopital de Purpan, Toulouse, France

    M Attal

  9. Department of Hematology, Radboud University—Nijmegen Medical Centre, Nijmegen, The Netherlands

    N Schaap

  10. Service Hematologie, Centre Hospitalier Lyon Sud, Lyon, France

    M Michallet

  11. Department of Hematology, Centre Hospitalier Universitaire Brabois, Vandoeuvre les Nancy, France

    C Bonmati

  12. BMT Centre Leiden, Leiden University Hospital, Leiden, The Netherlands

    H Veelken

Authors
  1. T Czerw
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Labopin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N-C Gorin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Giebel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P-Y Dumas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Foa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Attal
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N Schaap
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Michallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C Bonmati
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. H Veelken
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Czerw.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Czerw, T., Labopin, M., Gorin, NC. et al. Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant 49, 950–954 (2014). https://doi.org/10.1038/bmt.2014.64

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.64

This article is cited by

Search

Advanced search

Quick links